The role of fecal biomarkers in individuals with inflammatory bowel disease

References

• Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–317. doi: 10.1038/nature10209
   PubMed Web of Science ®Google Scholar
• Thurgate LE, Lemberg DA, Day AS, et al. An overview of inflammatory bowel disease unclassified in children. Inflamm Intest Dis. 2019;4(3):97–103. doi: 10.1159/000501519
   PubMedGoogle Scholar
• Cao L, Dayimu A, Guan X, et al. Global evolving patterns and cross-country inequalities of inflammatory bowel disease burden from 1990 to 2019: a worldwide report. Inflamm Res. 2024;73(2):277–287. doi: 10.1007/s00011-023-01836-7
   PubMed Web of Science ®Google Scholar
• Mak JWY, Sun Y, Limsrivilai J, et al. Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21st century (GIVES-21). BMC Med Res Methodol. 2023;23(1):129. doi: 10.1186/s12874-023-01944-2
   PubMed Web of Science ®Google Scholar
• Vernon-Roberts A, Aluzaite K, Khalilipour B, et al. Systematic review of diagnostic delay for children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2023;76(3):304–312. doi: 10.1097/MPG.0000000000003670
   PubMed Web of Science ®Google Scholar
• Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58(6):795–806. doi: 10.1097/MPG.0000000000000239
   PubMed Web of Science ®Google Scholar
• Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scan J Gastroenterol. 1992;27(9):793–798. doi: 10.3109/00365529209011186
   PubMed Web of Science ®Google Scholar
• Colombel JF, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology. 2017;152(2):351–61.e5. doi: 10.1053/j.gastro.2016.09.046
   PubMed Web of Science ®Google Scholar
• Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55(3):426–431. doi: 10.1136/gut.2005.069476
   PubMed Web of Science ®Google Scholar
• Teigelkamp S, Bhardwaj RS, Roth J, et al. Calcium-dependent complex assembly of the myeloic differentiation proteins mrp-8 and mrp-14. J Biol Chem. 1991;266(20):13462–13467. doi: 10.1016/S0021-9258(18)98862-9
   PubMed Web of Science ®Google Scholar
• Striz I, Trebichavsky I. Calprotectin – a pleiotropic molecule in acute and chronic inflammation. Physiol Res. 2004;53:245–253. doi: 10.33549/physiolres.930448
   PubMed Web of Science ®Google Scholar
• Rammes A, Roth J, Goebeler M, et al. Myeloid-related protein (mrp) 8 and mrp14, calcium-binding proteins of the s100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem. 1997;272(14):9496–9502. doi: 10.1074/jbc.272.14.9496
   PubMed Web of Science ®Google Scholar
• Hetland G, Talgo GJ, Fagerhol MK. Chemotaxins c5a and fmlp induce release of calprotectin (leucocyte l1 protein) from polymorphonuclear cells in vitro. Mol Pathol. 1998;51(3):143–148. doi: 10.1136/mp.51.3.143
   PubMedGoogle Scholar
• Besold AN, Gilston BA, Radin JN, et al. Role of calprotectin in withholding zinc and copper from Candida albicans. Infect Immun. 2017;86(2):1–16. doi: 10.1128/IAI.00779-17
   Web of Science ®Google Scholar
• Nakashige TG, Nolan EM. Human calprotectin affects the redox speciation of iron. Metallomics. 2017;9:1086–1095. doi: 10.1039/C7MT00044H
   PubMed Web of Science ®Google Scholar
• Nakashige TG, Zhang B, Krebs C, et al. Human calprotectin is an iron-sequestering host-defense protein. Nat Chem Biol. 2015;11:765–771. doi: 10.1038/nchembio.1891
   PubMed Web of Science ®Google Scholar
• Brophy MB, Hayden JA, Nolan EM. Calcium ion gradients modulate the zinc affinity and antibacterial activity of human calprotectin. J Am Chem Soc. 2012;134(43):18089–18100. doi: 10.1021/ja307974e
   PubMed Web of Science ®Google Scholar
• Pruenster M, Vogl T, Roth J, et al. S100a8/a9: from basic science to clinical application. Pharmacol Therapeu. 2016;167:120–131. doi: 10.1016/j.pharmthera.2016.07.015
   PubMed Web of Science ®Google Scholar
• Golden BE, Clohessy PA, Russell G, et al. Calprotectin as a marker of inflammation in cystic fibrosis. Arch Dis Child. 1996;74(2):136–139. doi: 10.1136/adc.74.2.136
   PubMed Web of Science ®Google Scholar
• Gray RD, Imrie M, Boyd AC, et al. Sputum and serum calprotectin are useful biomarkers during CF exacerbation. J Cyst Fibros. 2010;9(3):193–198. doi: 10.1016/j.jcf.2010.01.005
   PubMed Web of Science ®Google Scholar
• Abildtrup M, Kingsley GH, Scott DL. Calprotectin as a biomarker for rheumatoid arthritis: a systematic review. J Rheumatol. 2015;42:760–770. doi: 10.3899/jrheum.140628
   PubMed Web of Science ®Google Scholar
• Jensen LJ, Kistorp C, Bjerre M, et al. Plasma calprotectin levels reflect disease severity in patients with chronic heart failure. Eur J Prev Cardiol. 2012;19(5):999–1004. doi: 10.1177/1741826711421078
   PubMed Web of Science ®Google Scholar
• Berg-Hansen P, Vandvik B, Fagerhol M, et al. Calprotectin levels in the cerebrospinal fluid reflect disease activity in multiple sclerosis. J Neuroimmunol. 2009;216(1–2):98–102. doi: 10.1016/j.jneuroim.2009.09.006
   PubMed Web of Science ®Google Scholar
• Muller F, Froland SS, Aukrust P, et al. Elevated serum calprotectin levels in HIV-infected patients: the calprotectin response during zdv treatment is associated with clinical events. J Acquir Immun Defic Syndr. 1994;7:931–939.
   PubMed Web of Science ®Google Scholar
• Kristinsson J, Armbruster CH, Ugstad M, et al. Fecal excretion of calprotectin in colorectal cancer: relationship to tumor characteristics. Scand J Gastroenterol. 2001;36(2):202–207. doi: 10.1080/003655201750065979
   PubMed Web of Science ®Google Scholar
• Blanco-Prieto S, Vazquez-Iglesias L, Rodriguez-Girondo M, et al. Serum calprotectin, cd26 and egf to establish a panel for the diagnosis of lung cancer. PLOS ONE. 2015;10(5):e0127318. doi: 10.1371/journal.pone.0127318
   PubMed Web of Science ®Google Scholar
• Stroncek DF, Shankar RA, Skubitz KM. The subcellular distribution of myeloid-related protein 8 (mrp8) and mrp14 in human neutrophils. J Translat Med. 2005;3(1):36–. doi: 10.1186/1479-5876-3-36
   PubMedGoogle Scholar
• Yui S, Nakatani Y, Mikami M. Calprotectin (s100a8/s100a9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol Pharmaceuti Bull. 2003;26(6):753–760. doi: 10.1248/bpb.26.753
   PubMed Web of Science ®Google Scholar
• Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull Eur Physiopathol Respir. 1980;16(Suppl):273–282.
   PubMedGoogle Scholar
• Dale I, Fagerhol MK, Naesgaard I. Purification and partial characterization of a highly immunogenic human leukocyte protein, the l1 antigen. Eur J Biochem. 1983;134(1):1–6. doi: 10.1111/j.1432-1033.1983.tb07522.x
   PubMedGoogle Scholar
• Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999;34(1):50–54. doi: 10.1080/00365529950172835
   PubMed Web of Science ®Google Scholar
• Hoskin TS, Crowther JM, Cheung J, et al. Oxidative cross-linking of calprotectin occurs in vivo, altering its structure and susceptibility to proteolysis. Redox Biol. 2019;24:101202. doi: 10.1016/j.redox.2019.101202
   PubMed Web of Science ®Google Scholar
• Edwards TS, Dickerhof N, Magon NJ, et al. Formation of calprotectin-derived peptides in the airways of children with cystic fibrosis. J Immunol. 2022;208(4):979–990. doi: 10.4049/jimmunol.2001017
   PubMed Web of Science ®Google Scholar
• Deputy M, Devanaboina R, Al Bakir I, et al. The role of faecal calprotectin in the diagnosis of inflammatory bowel disease. B Med J. 2023;380:e068947. doi: 10.1136/bmj-2021-068947
   PubMedGoogle Scholar
• Petryszyn P, Staniak A, Wolosianska A, et al. Faecal calprotectin as a diagnostic marker of inflammatory bowel disease in patients with gastrointestinal symptoms: meta-analysis. Eur J Gastroenterol Hepatol. 2019;31(11):1306–1312. doi: 10.1097/MEG.0000000000001509
   PubMed Web of Science ®Google Scholar
• Joshi S, Lewis SJ, Creanor S, et al. Age-related faecal calprotectin, lactoferrin and tumour m2-pk concentrations in healthy volunteers. Ann Clin Biochem. 2010;47:259–263. doi: 10.1258/acb.2009.009061
   PubMed Web of Science ®Google Scholar
• Velasco Rodríguez-Belvís M, Viada Bris JF, Plata Fernández C, et al. Normal fecal calprotectin levels in healthy children are higher than in adults and decrease with age. Paediatr Child Health. 2020;25(5):286–292. doi: 10.1093/pch/pxz070
   PubMed Web of Science ®Google Scholar
• Hestvik E, Tumwine JK, Tylleskar T, et al. Faecal calprotectin concentrations in apparently healthy children aged 0-12 years in urban kampala, uganda: a community-based survey. BMC Pediatr. 2011;11:9. doi: 10.1186/1471-2431-11-9
   PubMed Web of Science ®Google Scholar
• Meling TR, Aabakken L, Røseth A, et al. Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs. Scan J Gastroenterol. 1996;31(4):339–344. doi: 10.3109/00365529609006407
   PubMed Web of Science ®Google Scholar
• Berni Canani R, Rapacciuolo L, Romano MT, et al. Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. Dig Liver Dis. 2004;36(7):467–470. doi: 10.1016/j.dld.2004.02.009
   PubMedGoogle Scholar
• Holtman GA, Lisman-van Leeuwen Y, Kollen BJ, et al. Diagnostic accuracy of fecal calprotectin for pediatric inflammatory bowel disease in primary care: a prospective cohort study. Ann Fam Med. 2016;14(5):437–445. doi: 10.1370/afm.1949
   PubMed Web of Science ®Google Scholar
• Jusué V, Chaparro M, Gisbert JP. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease. Dig Liver Dis. 2018;50(4):353–359. doi: 10.1016/j.dld.2017.12.022
   PubMedGoogle Scholar
• Vernia F, Di Ruscio M, Stefanelli G, et al. Is fecal calprotectin an accurate marker in the management of Crohn’s disease? J Gastroenterol Hepatol. 2020;35(3):390–400. doi: 10.1111/jgh.14950
   PubMed Web of Science ®Google Scholar
• Pauwels RWM, de Vries AC, van der Woude CJ. Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: a simple algorithm for clinical practice. J Gastroenterol Hepatol. 2020;35(11):1893–1901. doi: 10.1111/jgh.15063
   PubMed Web of Science ®Google Scholar
• Benitez JM, Meuwis MA, Reenaers C, et al. Role of endoscopy, cross-sectional imaging and biomarkers in Crohn’s disease monitoring. Gut. 2013;62(12):1806–1816. doi: 10.1136/gutjnl-2012-303957
   PubMed Web of Science ®Google Scholar
• Xiang BJ, Jiang M, Sun MJ, et al. Optimal range of fecal calprotectin for predicting mucosal healing in patients with inflammatory bowel disease: a systematic review and meta-analysis. Visc Med. 2021;37:338–348. doi: 10.1159/000514196
   PubMed Web of Science ®Google Scholar
• Chen F, Hu Y, Fan YH, et al. Clinical value of fecal calprotectin in predicting mucosal healing in patients with ulcerative colitis. Front Med (Lausanne). 2021;8:679264. doi: 10.3389/fmed.2021.679264
   PubMed Web of Science ®Google Scholar
• Bertani L, Blandizzi C, Mumolo MG, et al. Fecal calprotectin predicts mucosal healing in patients with ulcerative colitis treated with biological therapies: a prospective study. Clin Transl Gastroenterol. 2020;11:e00174. doi: 10.14309/ctg.0000000000000174
   PubMed Web of Science ®Google Scholar
• Kristensen V, Røseth A, Ahmad T, et al. Fecal calprotectin: a reliable predictor of mucosal healing after treatment for active ulcerative colitis. Gastroenterol Res Pract. 2017;2017:1–5. doi: 10.1155/2017/2098293
   Web of Science ®Google Scholar
• Zittan E, Kelly OB, Kirsch R, et al. Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic crohnʼs disease. Inflamm Bowel Dis. 2016;22(3):623–630. doi: 10.1097/MIB.0000000000000652
   PubMed Web of Science ®Google Scholar
• Kawashima K, Oshima N, Kishimoto K, et al. Low fecal calprotectin predicts histological healing in patients with ulcerative colitis with endoscopic remission and leads to prolonged clinical remission. Inflamm Bowel Dis. 2023;29(3):359–366. doi: 10.1093/ibd/izac095
   PubMed Web of Science ®Google Scholar
• Chew TS, Mansfield JC. Can faecal calprotectin predict relapse in inflammatory bowel disease: a mini review. Frontline Gastroenterol. 2018;9:23–28. doi: 10.1136/flgastro-2016-100686
   PubMedGoogle Scholar
• Mooiweer E, Severs M, Schipper ME, et al. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. J Crohn’s Colitis. 2015;9(1):50–55. doi: 10.1093/ecco-jcc/jju003
   Google Scholar
• Scaioli E, Scagliarini M, Cardamone C, et al. Clinical application of faecal calprotectin in ulcerative colitis patients. Eur J Gastroenterol Hepatol. 2015;27(12):1418–1424. doi: 10.1097/MEG.0000000000000461
   PubMed Web of Science ®Google Scholar
• Ferreiro-Iglesias R, Barreiro-de Acosta M, Otero Santiago M, et al. Fecal calprotectin as predictor of relapse in patients with inflammatory bowel disease under maintenance infliximab therapy. J Clin Gastroenterol. 2016;50(2):147–151. doi: 10.1097/MCG.0000000000000312
   PubMed Web of Science ®Google Scholar
• Wright EK, Kamm MA, De Cruz P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of crohn’s disease after surgery. Gastroenterology. 2015;148(5):938–947.e1. doi: 10.1053/j.gastro.2015.01.026.
   PubMed Web of Science ®Google Scholar
• Tham YS, Yung DE, Fay S, et al. Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn’s disease: systematic review and meta-analysis. Therap Adv Gastroenterol. 2018;11. 11:1756284818785571. doi: 10.1177/1756284818785571
   Web of Science ®Google Scholar
• Fukunaga S, Kuwaki K, Mitsuyama K, et al. Detection of calprotectin in inflammatory bowel disease: fecal and serum levels and immunohistochemical localization. Int J Mol Med. 2018;41:107–118. doi: 10.3892/ijmm.2017.3244
   PubMed Web of Science ®Google Scholar
• Bryce C, Bucaj M. Fecal calprotectin for the evaluation of inflammatory bowel disease. Am Fam Physician. 2021;104:303–304.
   PubMed Web of Science ®Google Scholar
• Winterbourn CC, Kettle AJ, Hampton MB. Reactive oxygen species and neutrophil function. Annu Rev Biochem. 2016;85(1):765–792. doi: 10.1146/annurev-biochem-060815-014442
   PubMedGoogle Scholar
• Fenna R, Zeng J, Davey C. Structure of the green heme in myeloperoxidase. Arch Biochem Biophys. 1995;316(1):653–656. doi: 10.1006/abbi.1995.1086
   PubMed Web of Science ®Google Scholar
• Winterbourn CC, Hampton MB, Livesey JH, et al. Modeling the reactions of superoxide and myeloperoxidase in the neutrophil phagosome: implications for microbial killing. The J Biol Chem. 2006;281(52):39860–39869. doi: 10.1074/jbc.M605898200
   PubMed Web of Science ®Google Scholar
• Wright HL, Moots RJ, Bucknall RC, et al. Neutrophil function in inflammation and inflammatory diseases. Rheumatology. 2010;49:1618–1631. doi: 10.1093/rheumatology/keq045
   PubMed Web of Science ®Google Scholar
• Amulic B, Cazalet C, Hayes GL, et al. Neutrophil function: from mechanisms to disease. Ann Rev Immunol. 2012;30(1):459–489. doi: 10.1146/annurev-immunol-020711-074942
   PubMedGoogle Scholar
• Zhou GX, Liu ZJ. Potential roles of neutrophils in regulating intestinal mucosal inflammation of inflammatory bowel disease. J Dig Dis. 2017;18(9):495–503. doi: 10.1111/1751-2980.12540
   PubMed Web of Science ®Google Scholar
• Dickerhof N, Pearson JF, Hoskin TS, et al. Oxidative stress in early cystic fibrosis lung disease is exacerbated by airway glutathione deficiency. Free RAD Biol Med. 2017;113:236–243. doi: 10.1016/j.freeradbiomed.2017.09.028.
   PubMed Web of Science ®Google Scholar
• Pillinger MH, Abramson SB. The neutrophil in rheumatoid arthritis. Rheum Dis Clinic North Am. 1995;21(3):691–714. doi: 10.1016/S0889-857X(21)00463-4
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005;25(6):1102–1111. doi: 10.1161/01.ATV.0000163262.83456.6d
   PubMed Web of Science ®Google Scholar
• Lampinen M, Backman M, Winqvist O, et al. Different regulation of eosinophil activity in crohn’s disease compared with ulcerative colitis. J Leuk Biol. 2008;84(6):1392–1399. doi: 10.1189/jlb.0807513
   PubMed Web of Science ®Google Scholar
• Chami B, Martin NJJ, Dennis JM, et al. Myeloperoxidase in the inflamed colon: a novel target for treating inflammatory bowel disease. Arch Biochem Biophys. 2018;645:61–71. doi: 10.1016/j.abb.2018.03.012
   PubMed Web of Science ®Google Scholar
• Saiki T. Myeloperoxidase concentrations in the stool as a new parameter of inflammatory bowel disease. Kurume Med J. 1998;45(1):69–73. doi: 10.2739/kurumemedj.45.69
   PubMedGoogle Scholar
• Peterson CG, Sangfelt P, Wagner M, et al. Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis. Scand J Clin Lab Invest. 2007;67(8):810–820. doi: 10.1080/00365510701452838
   PubMed Web of Science ®Google Scholar
• Masoodi I, Kochhar R, Dutta U, et al. Evaluation of fecal myeloperoxidase as a biomarker of disease activity and severity in ulcerative colitis. Dig Dis Sci. 2012;57:1336–1340. doi: 10.1007/s10620-012-2027-5
   PubMed Web of Science ®Google Scholar
• Peterson CG, Eklund E, Taha Y, et al. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol. 2002;97(7):1755–1762. doi: 10.1111/j.1572-0241.2002.05837.x
   PubMed Web of Science ®Google Scholar
• Sugi K, Saitoh O, Hirata I, et al. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol. 1996;91:927–934.
   PubMed Web of Science ®Google Scholar
• Peterson CG, Lampinen M, Hansson T, et al. Evaluation of biomarkers for ulcerative colitis comparing two sampling methods: fecal markers reflect colorectal inflammation both macroscopically and on a cellular level. Scand J Clin Lab Invest. 2016;76(5):393–401. doi: 10.1080/00365513.2016.1185145
   PubMed Web of Science ®Google Scholar
• Silberer H, Küppers B, Mickisch O, et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab. 2005;51:117–126.
   PubMed Web of Science ®Google Scholar
• Wagner M, Peterson CG, Ridefelt P, et al. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol. 2008;14(36):5584–5589. doi: 10.3748/wjg.14.5584
   PubMed Web of Science ®Google Scholar
• Swaminathan A, Borichevsky GM, Edwards TS, et al. Faecal myeloperoxidase as a biomarker of endoscopic activity in inflammatory bowel disease. J Crohn’s Colitis. 2022;16(12):1862–1873. doi: 10.1093/ecco-jcc/jjac098
   Google Scholar
• Miranda LP, Tao T, Jones A, et al. Total chemical synthesis and chemotactic activity of human s100a12 (en-rage). FEBS Lett. 2001;488:85–90. doi: 10.1016/S0014-5793(00)02392-9
   PubMed Web of Science ®Google Scholar
• Yang Z, Tao T, Raftery MJ, et al. Proinflammatory properties of the human s100 protein s100a12. J Leukoc Biol. 2001;69(6):986–994. doi: 10.1189/jlb.69.6.986
   PubMed Web of Science ®Google Scholar
• Vogl T, Pröpper C, Hartmann M, et al. S100a12 is expressed exclusively by granulocytes and acts independently from mrp8 and mrp14. J Biol Chem. 1999;274(36):25291–25296. doi: 10.1074/jbc.274.36.25291
   PubMed Web of Science ®Google Scholar
• Carvalho A, Lu J, Francis JD, et al. S100a12 in digestive diseases and health: a scoping review. Gastroenterol Res Pract. 2020;2020:1–11. doi: 10.1155/2020/2868373
   Web of Science ®Google Scholar
• Ciccocioppo R, Imbesi V, Betti E, et al. The circulating level of soluble receptor for advanced glycation end products displays different patterns in ulcerative colitis and crohn’s disease: a cross-sectional study. Dig Dis Sci. 2015;60:2327–2337. doi: 10.1007/s10620-015-3619-7
   PubMed Web of Science ®Google Scholar
• Witarto BS, Visuddho V, Witarto AP, et al. Performance of fecal s100a12 as a novel non-invasive diagnostic biomarker for pediatric inflammatory bowel disease: a systematic review and meta-analysis. J Pediatr (Rio J). 2023;99(5):432–442. doi: 10.1016/j.jped.2023.03.002
   PubMed Web of Science ®Google Scholar
• Ciccocioppo R, Vanoli A, Klersy C, et al. Role of the advanced glycation end products receptor in crohn’s disease inflammation. World J Gastroenterol. 2013;19(45):8269–8281. doi: 10.3748/wjg.v19.i45.8269
   PubMed Web of Science ®Google Scholar
• Foell D, Kucharzik T, Kraft M, et al. Neutrophil derived human s100a12 (en-rage) is strongly expressed during chronic active inflammatory bowel disease. Gut. 2003;52(6):847–853. doi: 10.1136/gut.52.6.847
   PubMed Web of Science ®Google Scholar
• Galgut BJ, Lemberg DA, Day AS, et al. The value of fecal markers in predicting relapse in inflammatory bowel diseases. Front Pediatr. 2017;5:292. doi: 10.3389/fped.2017.00292
   PubMed Web of Science ®Google Scholar
• de Vijver EV, Heida A, Ioannou S, et al. Test strategies to predict inflammatory bowel disease among children with nonbloody diarrhea. Pediatrics. 2020;146(2). doi: 10.1542/peds.2019-2235
   Web of Science ®Google Scholar
• Heida A, Van de Vijver E, van Ravenzwaaij D, et al. Predicting inflammatory bowel disease in children with abdominal pain and diarrhoea: calgranulin-c versus calprotectin stool tests. Arch Dis Child. 2018;103:565–571. doi: 10.1136/archdischild-2017-314081
   PubMed Web of Science ®Google Scholar
• Lopez RN, Leach ST, Lemberg DA, et al. Fecal biomarkers in inflammatory bowel disease. J Gastroenterol Hepatol. 2017;32:577–582. doi: 10.1111/jgh.13611
   PubMed Web of Science ®Google Scholar
• Day AS, Ehn M, Gearry RB, et al. Fecal s100a12 in healthy infants and children. Dis Markers. 2013;35:295–299. doi: 10.1155/2013/873582
   PubMed Web of Science ®Google Scholar
• Kaiser T, Langhorst J, Wittkowski H, et al. Faecal s100a12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut. 2007;56:1706–1713. doi: 10.1136/gut.2006.113431
   PubMed Web of Science ®Google Scholar
• Manolakis AC, Kapsoritakis AN, Georgoulias P, et al. Moderate performance of serum s100a12, in distinguishing inflammatory bowel disease from irritable bowel syndrome. BMC Gastroenterol. 2010;10:118. doi: 10.1186/1471-230X-10-118
   PubMed Web of Science ®Google Scholar
• Whitehead SJ, Ford C, Gama RM, et al. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal s100a12. J Clin Pathol. 2017;70:1049–1056. doi: 10.1136/jclinpath-2017-204340
   PubMed Web of Science ®Google Scholar
• Lee SH, Hwang SW, Park SH, et al. Fecal s100a12 is associated with future hospitalization and step-up of medical treatment in patients with crohn’s disease in clinical remission: a pilot study. Intest Res. 2022;20:203–212. doi: 10.5217/ir.2021.00020
   PubMed Web of Science ®Google Scholar
• Foell D, Kane D, Bresnihan B, et al. Expression of the pro-inflammatory protein s100a12 (en-rage) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford). 2003;42(11):1383–1389. doi: 10.1093/rheumatology/keg385
   PubMed Web of Science ®Google Scholar
• Gerss J, Roth J, Holzinger D, et al. Phagocyte-specific s100 proteins and high-sensitivity c reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann Rheum Dis. 2012;71:1991–1997. doi: 10.1136/annrheumdis-2012-201329
   PubMed Web of Science ®Google Scholar
• Foell D, Seeliger S, Vogl T, et al. Expression of s100a12 (en-rage) in cystic fibrosis. Thorax. 2003;58(7):613–617. doi: 10.1136/thorax.58.7.613
   PubMed Web of Science ®Google Scholar
• Li Y, He Y, Chen S, et al. S100a12 as biomarker of disease severity and prognosis in patients with idiopathic pulmonary fibrosis. Front Immunol. 2022;13:810338. doi: 10.3389/fimmu.2022.810338
   PubMed Web of Science ®Google Scholar
• Hunt WR, Helfman BR, Na M, et al. Advanced glycation end products are elevated in cystic fibrosis-related diabetes and correlate with worse lung function. J Cyst Fibros. 2016;15(5):681–688. doi: 10.1016/j.jcf.2015.12.011
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zha Y, Yang Y, et al. S100 proteins in cardiovascular diseases. Mol Med. 2023;29:68. doi: 10.1186/s10020-023-00662-1
   PubMed Web of Science ®Google Scholar
• Dai C, Jiang M, Sun MJ, et al. Fecal lactoferrin for assessment of inflammatory bowel disease activity: a systematic review and meta-analysis. J Clin Gastroenterol. 2020;54(6):545–553. doi: 10.1097/MCG.0000000000001212
   PubMed Web of Science ®Google Scholar
• Abraham BP. Fecal lactoferrin testing. Gastroenterol Hepatol (NY). 2018;14:713–716.
   PubMedGoogle Scholar
• Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(11):1746–1754. doi: 10.1002/ibd.20920
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Shiraki M, Bamba T, et al. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with crohn’s disease after ileocolonic resection: a prospective pilot study. United European Gastroenterol J. 2013;1(5):368–374. doi: 10.1177/2050640613501818
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Shiraki M, Bamba T, et al. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. Intern J Colorectal Dis. 2014;29(4):485–491. doi: 10.1007/s00384-013-1817-3
   PubMed Web of Science ®Google Scholar
• Vernia F, Viscido A, Di Ruscio M, et al. Fecal lactoferrin and other putative fecal biomarkers in crohn’s disease: do they still have a potential clinical role? Digestion. 2021;102:833–844. doi: 10.1159/000518419
   PubMed Web of Science ®Google Scholar
• Lykowska-Szuber L, Klimczak K, Eder P, et al. Diagnostic importance of faecal markers in long-term monitoring of anti-TNF-? therapy in primary responders with Crohn’s disease. Prz Gastroenterol. 2016;4:232–238. doi: 10.5114/pg.2015.55700
   Google Scholar
• Sorrentino D, Nguyen VQ, Love K. Fecal lactoferrin predicts primary nonresponse to biologic agents in inflammatory bowel disease. Dig Dis. 2021;39:626–633. doi: 10.1159/000515432
   PubMed Web of Science ®Google Scholar
• Zhou XL, Xu W, Tang XX, et al. Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis. BMC Gastroenterol. 2014;14:121. doi: 10.1186/1471-230X-14-121
   PubMed Web of Science ®Google Scholar
• Cao B, Zhou X, Ma J, et al. Role of mirnas in inflammatory bowel disease. Dig Dus Sci. 2017;62(6):1426–1438. doi: 10.1007/s10620-017-4567-1
   PubMed Web of Science ®Google Scholar
• Weber JA, Baxter DH, Zhang S, et al. The microrna spectrum in 12 body fluids. Clin Chem. 2010;56(11):1733–1741. doi: 10.1373/clinchem.2010.147405
   PubMed Web of Science ®Google Scholar
• Igaz I, Igaz P. Diagnostic relevance of micrornas in other body fluids including urine, feces, and saliva. Exp Suppl. 2015;106:245–252.
   PubMedGoogle Scholar
• Wohnhaas CT, Schmid R, Rolser M, et al. Fecal micrornas show promise as noninvasive crohn’s disease biomarkers. Crohns Colitis. 2020;2(1):otaa003. doi: 10.1093/crocol/otaa003
   PubMedGoogle Scholar
• Wang H, Zhang S, Yu Q, et al. Circulating microrna223 is a new biomarker for inflammatory bowel disease. Medicine (Baltimore). 2016;95:e2703. doi: 10.1097/MD.0000000000002703
   PubMed Web of Science ®Google Scholar
• Mohammadi A, Kelly OB, Smith MI, et al. Differential mirna expression in ileal and colonic tissues reveals an altered immunoregulatory molecular profile in individuals with crohn’s disease versus healthy subjects. J Crohn’s Colitis. 2019;13(11):1459–1469. doi: 10.1093/ecco-jcc/jjz076
   Google Scholar
• Judit Béres N, Kiss Z, Müller KE, et al. Role of microRNA-223 in the regulation of poly(adp-ribose) polymerase in pediatric patients with crohn’s disease. Scand J Gastroenterol. 2018;53(9):1066–1073. doi: 10.1080/00365521.2018.1498915
   PubMed Web of Science ®Google Scholar
• Zhang J, Guo Z, Wang Z, et al. Fecal mir-223 is a noninvasive biomarker for estimating crohn’s disease activity. Immun Inflam Dis. 2023;11(12):e1131. doi: 10.1002/iid3.1131
   PubMed Web of Science ®Google Scholar
• Sáez-González E, Moret-Tatay I, Bastida G, et al. Microrna and granulocyte-monocyte adsorption apheresis combotherapy after inadequate response to anti-tnf agents in ulcerative colitis. J Clin Apher. 2023;39(1). doi: 10.1002/jca.22101
   PubMed Web of Science ®Google Scholar
• Stallhofer J, Friedrich M, Konrad-Zerna A, et al. Lipocalin-2 is a disease activity marker in inflammatory bowel disease regulated by il-17a, il-22, and tnf-α and modulated by il23r genotype status. Inflamm Bowel Dis. 2015;21:1–40. doi: 10.1097/MIB.0000000000000515
   PubMed Web of Science ®Google Scholar
• Reghefaoui M, Peresuodei TS, Saavedra Palacios MS, et al. The role of serological markers in the prediction of disease course and response to therapy in inflammatory bowel disease. Cureus. 2023;15:e48442. doi: 10.7759/cureus.48442
   PubMed Web of Science ®Google Scholar
• Oikonomou KA, Kapsoritakis AN, Theodoridou C, et al. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity. J Gastroenterol. 2012;47:519–530. doi: 10.1007/s00535-011-0516-5
   PubMed Web of Science ®Google Scholar
• Ashcroft AJ, Cruickshank SM, Croucher PI, et al. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity. 2003;19(6):849–861. doi: 10.1016/S1074-7613(03)00326-1
   PubMed Web of Science ®Google Scholar
• Franchimont N, Reenaers C, Lambert C, et al. Increased expression of receptor activator of NF- κ B ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn’s disease patients. Clin Exp Immunol. 2004;138(3):491–498. doi: 10.1111/j.1365-2249.2004.02643.x
   PubMed Web of Science ®Google Scholar
• Moschen AR, Kaser A, Enrich B, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut. 2005;54(4):479–487. doi: 10.1136/gut.2004.044370
   PubMed Web of Science ®Google Scholar
• Stanisławowski M, Wiśniewski P, Guzek M, et al. Influence of receptor activator of nuclear factor kappa B ligand, osteoprotegerin and interleukin-33 on bone metabolism in patients with long-standing ulcerative colitis. J Crohns Colitis. 2014;8(8):802–810. doi: 10.1016/j.crohns.2013.12.021
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Sargent M, Leslie WD. Serum osteoprotegerin is increased in Crohn’s disease: a population-based case control study. Inflamm Bowel Dis. 2005;11(4):325–330. doi: 10.1097/01.MIB.0000164015.60795.ca
   PubMed Web of Science ®Google Scholar
• Nahidi L, Leach ST, Sidler MA, et al. Osteoprotegerin in pediatric Crohn’s disease and the effects of exclusive enteral nutrition. Inflamm Bowel Dis. 2011;17(2):516–523. doi: 10.1002/ibd.21361
   PubMed Web of Science ®Google Scholar
• von Tirpitz C, Epp S, Klaus J, et al. Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn’s disease. Eur J Gastroenterol Hepatol. 2003;15(11):1165–1170. doi: 10.1097/00042737-200311000-00003
   PubMed Web of Science ®Google Scholar
• Miheller P, Muzes G, Rácz K, et al. Changes of OPG and RANKL concentrations in Crohn’s disease after infliximab therapy. Inflamm Bowel Dis. 2007;13(11):1379–1384. doi: 10.1002/ibd.20234
   PubMed Web of Science ®Google Scholar
• Sylvester FA, Turner D, Draghi A 2nd, et al. Fecal osteoprotegerin may guide the introduction of second-line therapy in hospitalized children with ulcerative colitis. Inflamm Bowel Dis. 2011 Aug;17(8):1726–1730. doi: 10.1002/ibd.21561
   PubMed Web of Science ®Google Scholar
• Leach ST, Day AS, Messenger R, et al. Fecal markers of inflammation and disease activity in pediatric crohn disease: results from the ImageKids study. J Pediatr Gastroenterol Nutr. 2020;70(5):580–585. doi: 10.1097/MPG.0000000000002615
   PubMed Web of Science ®Google Scholar
• Zhao T, Su Z, Li Y, et al. Chitinase-3 like-protein-1 function and its role in diseases. Sig Transduct Target Ther. 2020;5(1):201. doi: 10.1038/s41392-020-00303-7
   PubMed Web of Science ®Google Scholar
• Aomatsu T, Imaeda H, Matsumoto K, et al. Faecal chitinase 3-like-1: a novel biomarker of disease activity in paediatric inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34(8):941–948. doi: 10.1111/j.1365-2036.2011.04805.x
   PubMed Web of Science ®Google Scholar
• Santos GM, Ismael S, Morais J, et al. Intestinal alkaline phosphatase: a review of this enzyme role in the intestinal barrier function. Microorganisms. 2022;10(4):746. doi: 10.3390/microorganisms10040746
   PubMed Web of Science ®Google Scholar
• Ateş BB, Talim B, Gülşen HH, et al. Significance of intestinal alkaline phosphatase in predicting histological activity of pediatric inflammatory bowel disease. Turk J Pediatr. 2022;64(6):1068–1076. doi: 10.24953/turkjped.2021.5413
   PubMed Web of Science ®Google Scholar
• Sheng X, Liu D, Gamage SK, et al. Point-of-care monitoring of colitis using intestinal alkaline phosphatase in inflammatory bowel disease. ACS Sens. 2021;6(3):698–702. doi: 10.1021/acssensors.0c02177
   PubMed Web of Science ®Google Scholar
• Jia Z, Zhang Y, Zhang C, et al. Biosensing intestinal alkaline phosphatase by pregnancy test strips based on target-triggered CRISPR-Cas12a activity to monitor intestinal inflammation. Anal Chem. 2023;95(37):14111–14118. doi: 10.1021/acs.analchem.3c03099
   PubMed Web of Science ®Google Scholar
• Hwang SW, Kim JH, Lee C, et al. Intestinal alkaline phosphatase ameliorates experimental colitis via toll-like receptor 4-dependent pathway. Eur J Pharmacol. 2018;820:156–166. doi: 10.1016/j.ejphar.2017.12.026
   PubMed Web of Science ®Google Scholar
• Chung-Faye G, Hayee B, Maestranzi S, et al. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation. Inflamm Bowel Dis. 2007;13(11):1374–1378. doi: 10.1002/ibd.20214
   PubMed Web of Science ®Google Scholar
• Day AS, Judd T, Lemberg DA, et al. Fecal M2-PK in children with Crohn’s disease: a preliminary report. Dig Dis Sci. 2012;57(8):2166–2170. doi: 10.1007/s10620-012-2215-3
   PubMed Web of Science ®Google Scholar
• Vázquez Morón JM, Pallarés Manrique H, Machancoses FH, et al. Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn’s disease with fecal calprotectin. Rev Esp Enferm Dig. 2017;109(2):130–136. doi: 10.17235/reed.2017.4542/2016
   PubMed Web of Science ®Google Scholar
• Roszak D, Gałęcka M, Cichy W, et al. Determination of faecal inflammatory marker concentration as a noninvasive method of evaluation of pathological activity in children with inflammatory bowel diseases. Adv Med Sci. 2015;60(2):246–252. doi: 10.1016/j.advms.2015.04.003
   PubMed Web of Science ®Google Scholar
• Czub E, Nowak JK, Szaflarska-Poplawska A, et al. Comparison of fecal pyruvate kinase isoform M2 and calprotectin in assessment of pediatric inflammatory bowel disease severity and activity. Acta Biochim Pol. 2014;61(1):99–102. doi: 10.18388/abp.2014_1929
   PubMed Web of Science ®Google Scholar
• Czub E, Nowak JK, Moczko J, et al. Fecal pyruvate kinase is not suitable for discrimination between inflammatory bowel disease exacerbation and acute gastroenteritis. Dev Period Med. 2015;19(2):167–173.
   PubMedGoogle Scholar
• Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut. 2010;59(9):1207–1212. doi: 10.1136/gut.2010.211755
   PubMed Web of Science ®Google Scholar
• Frin AC, Filippi J, Boschetti G, et al. Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis. Dig Liver Dis 2017 Jan;49(1):11–16. doi: 10.1016/j.dld.2016.09.001
   PubMedGoogle Scholar
• Overstreet AC, Anderson B, Burge M, et al. HMGB1 acts as an agent of host defense at the gut mucosal barrier. bioRxiv [Preprint]. 2023 May 30:2023.05.30.542477. doi: 10.1101/2023.05.30.542477
   Google Scholar
• Vitali R, Stronati L, Negroni A, et al. Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease. Am J Gastroenterol. 2011 Nov;106(11):2029–2040. doi: 10.1038/ajg.2011.231
   PubMed Web of Science ®Google Scholar
• Palone F, Vitali R, Cucchiara S, et al. Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014 Aug;20(8):1448–1457. doi: 10.1097/MIB.0000000000000113
   PubMed Web of Science ®Google Scholar
• Palone F, Vitali R, Cucchiara S, et al. Fecal HMGB1 reveals microscopic inflammation in adult and pediatric patients with inflammatory bowel disease in clinical and endoscopic remission. Inflamm Bowel Dis. 2016 Dec;22(12):2886–2893. doi: 10.1097/MIB.0000000000000938
   PubMed Web of Science ®Google Scholar
• Palone F, Vitali R, Cucchiara S, et al. Fecal HMGB1 reveals microscopic inflammation in adult and pediatric patients with inflammatory bowel disease in clinical and endoscopic remission. Inflamm Bowel Dis. 2016 Dec;22(12):2886–2893. doi: 10.1097/MIB.0000000000000938
   PubMed Web of Science ®Google Scholar